Cargando…

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia

Dyslipidemia is a treatable risk factor for atherosclerotic cardiovascular disease that can be addressed through lifestyle changes and/or lipid-lowering therapies. Adherence to statins can be a clinical challenge in some patients due to statin-associated muscle symptoms and other side effects. There...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Brian, Sikand, Geeta, Dineen, Elizabeth H., Malik, Shaista, Barseghian El-Farra, Ailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219430/ https://www.ncbi.nlm.nih.gov/pubmed/37240523 http://dx.doi.org/10.3390/jcm12103414

Ejemplares similares

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia
por: Sikand, Geeta, et al.
Publicado: (2023)

Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
por: Ungar, Leo, et al.
Publicado: (2018)

Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction
por: Chiesa, Giulia, et al.
Publicado: (2016)

Left ventricular free wall rupture as a result of delayed presentation of an inferior ST-elevation myocardial infarction due to fear of COVID-19: case report
por: Nasr, George H., et al.
Publicado: (2021)

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
por: Cicero, Arrigo F.G., et al.
Publicado: (2017)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Nutraceuticals: An integrative approach to starve Parkinson’s disease
por: Lama, Adriano, et al.
Publicado: (2020)

Nutraceuticals in prevention of cataract – An evidence based approach
por: Kaur, Amandeep, et al.
Publicado: (2017)

Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction
por: Sikand, Geeta, et al.
Publicado: (2020)

Lipid-lowering agents for dyslipidemia in patients who were infected with HIV in Taoyuan, Taiwan
por: Cheng, Shu-Hsing, et al.
Publicado: (2014)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China
por: Lu, Yuan, et al.
Publicado: (2021)

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study
por: Cicero, Arrigo F.G., et al.
Publicado: (2015)

Lipid-Based Nanocarrier System for the Effective Delivery of Nutraceuticals
por: Subramanian, Parthasarathi
Publicado: (2021)

Lipid Nanoparticles: An Effective Tool to Improve the Bioavailability of Nutraceuticals
por: Ashfaq, Rabia, et al.
Publicado: (2023)

Nutraceuticals and Food-Grade Lipid Nanoparticles: From Natural Sources to a Circular Bioeconomy Approach
por: Blanco-Llamero, Cristina, et al.
Publicado: (2022)

Preexisting right ventricular systolic dysfunction in high-risk patients undergoing non-emergent open abdominal surgery: A retrospective cohort study
por: Chou, Jody, et al.
Publicado: (2021)

A Nutraceutical Approach to Menopausal Complaints
por: De Franciscis, Pasquale, et al.
Publicado: (2019)

Effect of Abdominoplasty in the Lipid Profile of Patients with Dyslipidemia
por: Ramos-Gallardo, Guillermo, et al.
Publicado: (2013)

Dietary Lipids and Dyslipidemia in Chronic Kidney Disease
por: Kochan, Zdzislaw, et al.
Publicado: (2021)

Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia
por: Vanwong, Natchaya, et al.
Publicado: (2022)

Production of microalgae with high lipid content and their potential as sources of nutraceuticals
por: Udayan, Aswathy, et al.
Publicado: (2022)

Diabetes Dyslipidemia
por: Schofield, Jonathan D., et al.
Publicado: (2016)

Effect of the Administration of a Nutraceutical Supplement in Racehorses with Lower Airway Inflammation
por: Stucchi, Luca, et al.
Publicado: (2022)

Association Between the Awareness of Dyslipidemia and Health Behavior for Control of Lipid Levels Among Korean Adults with Dyslipidemia
por: Cho, In Young, et al.
Publicado: (2017)

A Modern Approach to Dyslipidemia
por: Berberich, Amanda J, et al.
Publicado: (2021)

Inventario ambiental : una aproximación desde la arquitectura una aproximación desde la arquitectura
por: Barseghian, Eduardo

Socioeconomic status and education level are associated with dyslipidemia in adults not taking lipid-lowering medication: a population-based study
por: Espírito Santo, Luçandra R, et al.
Publicado: (2019)

Dyslipidemia in subclinical hypothyroidism and the effect of thyroxine on lipid profile
por: Asranna, Ajay, et al.
Publicado: (2012)

Clinical considerations of lipid target and goal in dyslipidemia control
por: Wu, Na-Qiong, et al.
Publicado: (2016)

Nonfasting Lipid Profile May Suffice to Manage Dyslipidemia
por: Andrade, Chittaranjan
Publicado: (2020)

The Effect of BMI on Blood Lipids and Dyslipidemia in Lactating Women
por: Yu, Lianlong, et al.
Publicado: (2022)

Dietary and nutraceutical approach to type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2014)

Nutraceuticals: A Promising Therapeutic Approach in Ophthalmology
por: Castro-Castaneda, Carlos Rodrigo, et al.
Publicado: (2022)

Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial
por: Pirro, Matteo, et al.
Publicado: (2016)

Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
por: Yan, Xiaowei, et al.
Publicado: (2019)

Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia
por: Hu, Miao, et al.
Publicado: (2015)

Hypertension and Dyslipidemia Combined Therapeutic Approaches
por: Borghi, Claudio, et al.
Publicado: (2022)

Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen
por: Ni, Wen-Qing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_plcnol3ugdims5c3kff8c2jqkb